29644-22-2

Upstream product

• 5339-26-4 (4-nitrophenyl)ethyl bromide 
• 104-10-9 2-(4'-aminophenyl)ethyl alcohol 

Downstream Products

• 227467-45-0 ethyl N-[4-(2-bromoethyl)phenyl]aminoacetate 
• 218943-57-8 1-(2-bromoethyl)(4-t-butoxycarbonylamino)benzene 
• 227467-50-7 ethyl N-[2-bromo-4-(2-bromoethyl)phenyl]aminoacetate 
• 227467-51-8 ethyl N-[4-(2-bromoethyl)-2-iodophenyl]aminoacetate 
• 227467-49-4 ethyl N-[2,6-dibromo-4-(2-bromoethyl)phenyl]aminoacetate 
• 1027916-20-6 (4-{2-[(1S,2R)-2-Hydroxy-2-(4-hydroxy-phenyl)-1-methyl-ethylamino]-ethyl}-phenylamino)-acetic acid ethyl ester 
• 227467-86-9 ethyl N-[2-bromo-4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxyphenyl) methylethyl]amino]ethyl]phenyl]aminoacetate 
• 227467-88-1 ethyl N-[4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2-iodophenyl]aminoacetate 
• 227467-87-0 ethyl N-[2,6-dibromo-4-[2-[[(1S, 2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]phenyl]aminoacetate 
• 227467-46-1 2-[[4-(2-bromoethyl)phenyl]amino]-N,N-dimethylacetamide 

Relevant academic research and scientific papers

Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same

The present invention provides novel phenylaminoalkyl-carboxylic acid derivatives represented by the general formula: (wherein R1represents a hydroxy group, a lower alkoxy group, an aralkoxy group, an amino group, an alicyclic amino group or a mono or di(lower alkyl)amino group which may have a hydroxy group or a lower alkoxy group as a substituent; R2represents a hydrogen atom or a lower alkyl group; R3represents a hydrogen atom or a halogen atom; R4and R5are the same or different and each represents a hydrogen atom, a halogen atom or a lower alkyl group; A represents a lower alkylene group; the carbon atom marked with (R) represents a carbon atom in (R) configuration; and the carbon atom marked with (S) represents a carbon atom in (S) configuration) and pharmaceutically acceptable salts thereof, which have excellent β3-adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract.

Discovery of novel N-phenylglycine derivatives as potent and selective β3-adrenoceptor agonists for the treatment of frequent urination and urinary incontinence

With a novel assay using isolated ferret detrusor to estimate β3-adrenoceptor agonistic activity, we found that a series of glycine derivatives of ritodrine, a β2-adrenoceptor agonist, are potent β3-adrenoceptor agonists,

Molecular Armatures. Synthesis and Structure of Troegers Base Analogues Derived from 4-, 2,4-, 3,4-, and 2,4,5-Substituted Aniline Derivatives

The preparation of biomimetic systems designed to mimic natural receptor sites and enzymic active sites requires the development of new synthetic strategies for preparing large molecules with predictable and well-defined shapes.In this paper a number of derivatives of 6H,12H-5,11-methanodibenzodiazocines are prepared.The scope and limitations of the reaction of formaldehyde with aniline derivatives are examined.The molecules prepared have potential value as conformationally restricted armatures for the construction of biomimetic molecular systems.A crystallographic study reveals that the molecules are folded and that the angle formed by the two aryl rings ranges from 88 deg to 104 deg.Sulfonamides, bromides, alcohols, and amines can be introduced as side-chain substituents in these systems.